Related Experiment Video
Updated: Jun 13, 2025

TGF-β-mediated Endothelial to Mesenchymal Transition EndMT and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing
Published on: February 26, 2021
NORE1A loss promotes MASLD/MASH
Howard Donninger1, Katherine Hobbing2, Gavin E Arteel3
1Department of Medicine, University of Louisville, Louisville, KY, USA.
Abstract:
NORE1A (RASSF5) is a tumor suppressor that is frequently down-regulated in liver tumors. It is an upstream component of the HIPPO pathway, a key regulator of liver development and metabolism. HIPPO disruption can lead to the development of MASLD/MASH. While studying the phenotype of NORE1A knockout mice, we noticed that they exhibit no overt liver tumor phenotype, but have a strong propensity to develop fatty livers characteristic of MASLD/MASH. Additionally, knockdown of NORE1A in liver cells upregulates sterol regulator element binding protein 1 (SREBP1), whose deregulation is central to the development MASLD. Examination of primary human MASLD samples showed an inverse correlation between the expression of NORE1A protein and TAZ, a downstream effector of the HIPPO pathway. Thus, loss of NORE1A expression may contribute to the development of MASLD/MASH in humans and NORE1A knockout mice may provide a new MASLD/MASH model that more accurately mimics the human disease.
Insights
Loss of NORE1A, a tumor suppressor, promotes fatty liver disease (MASLD/MASH) by upregulating SREBP1. NORE1A deficiency may drive human MASLD, and NORE1A knockout mice offer a new disease model.
Area of Science:
- Hepatology
- Molecular Biology
- Oncology
Background:
- NORE1A (RASSF5) functions as a tumor suppressor and is often downregulated in liver cancer.
- It acts upstream in the HIPPO pathway, crucial for liver development and metabolism.
- HIPPO pathway disruption is linked to the pathogenesis of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH).
Purpose of the Study:
- To investigate the role of NORE1A in the development of liver disease, particularly MASLD/MASH.
- To explore the potential of NORE1A knockout mice as a model for human MASLD/MASH.
Main Methods:
- Phenotypic analysis of NORE1A knockout mice.
- Assessment of NORE1A knockdown effects on sterol regulatory element-binding protein 1 (SREBP1) expression in liver cells.
- Correlation analysis of NORE1A protein and TAZ expression in human MASLD samples.
Main Results:
- NORE1A knockout mice did not develop liver tumors but showed a strong propensity for fatty liver, characteristic of MASLD/MASH.
- NORE1A knockdown in liver cells led to increased SREBP1 expression, a key factor in MASLD development.
- Human MASLD samples exhibited an inverse correlation between NORE1A protein and TAZ expression.
Conclusions:
- Loss of NORE1A expression may contribute to the pathogenesis of MASLD/MASH in humans.
- NORE1A knockout mice represent a potential new preclinical model for studying human MASLD/MASH.
- Understanding NORE1A's role could reveal new therapeutic targets for fatty liver diseases.
Related Concept Videos
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Abnormal Proliferation
MicroRNAs
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

